For immediate release

==> picture [193 x 30] intentionally omitted <==

==> picture [55 x 28] intentionally omitted <==

==> picture [247 x 25] intentionally omitted <==

5 December 2018

Annual Research & Development Investor Briefing

Please find attached the presentation and an accompanying media release ahead of the Company’s Annual Research & Development Investor Briefing being held today commencing at 9am ADST.

The briefing will be webcast and can be accessed in the ‘Investor” section of the website – www.csl.com.au .

For further information, please contact:

Investors: Media: Mark Dehring Jemimah Brennan VP Investor Relations Head of Communications, Asia Pacific CSL Limited CSL Limited Telephone: +613 9389 3407 Mobile +61 412 635 483 Email: [email protected] Email: [email protected]

==> picture [93 x 7] intentionally omitted <==

==> picture [117 x 98] intentionally omitted <==

R&D Investor Briefing December 05, 2018 1 | Driven by Our Promise[™]

Legal Notice

Forward looking statements

The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these forward looking statements by the fact that they use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “may,” “assume,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, and CSL’s ability to protect its patents and other intellectual property. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of CSL.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including CSL). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, CSL disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of CSL since the date of these materials.

Trademarks

Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

2 | Driven by Our Promise[™]

Agenda

Welcome
Introduction and Highlights
Seqirus
Research & Early Development
Commercial Market Overview, Ig & Haemophilia

Mark Dehring Andrew Cuthbertson Gregg Sylvester Andrew Nash Bill Campbell

Q&A
Break –
Clinical Development Overview
Commercial Overview Specialty, Transplant, CSL112
Summary

Bill Mezzanotte Bill Campbell Bill Mezzanotte

3 | Driven by Our Promise[™]

Introduction and Highlights

Professor Andrew Cuthbertson AO Chief Scientific Officer

==> picture [409 x 429] intentionally omitted <==

4 | Driven by Our Promise[™]

Commitment to Research and Development

==> picture [685 x 312] intentionally omitted <==

----- Start of picture text -----

New Product Development
activities focus on innovative new therapies for life-
threatening diseases
Market Development
strategies seek to bring therapies to new markets
and new indications
Life Cycle Management
ensures continuous improvement of existing
products
Includes R&D for CSL Behring and Seqirus.
m = US$millions
----- End of picture text -----*

R&D investment ~10-11% global revenue

5 | Driven by Our Promise[™]

Key Past Launches from R&D Portfolio

==> picture [783 x 346] intentionally omitted <==

----- Start of picture text -----

2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
PRIVIGEN [®] HIZENTRA [®] PRIVIGEN [®] CIDP (US)
HIZENTRA [®]
PRIVIGEN [®] CIDP (EU) Ig IsoLo [®]
CIDP
BERINERT [® ] (US) KCENTRA [® ] (US) RESPREEZA [® ] (EU)
RIASTAP [®] CORIFACT [®] HAEGARDA [® ] (US)
VONCENTO [® ] (EU)
IDELVION [®]
AFSTYLA [®]
AFLURIA [® ] QIV FLUAD [® ] UK
AFLURIA [®]
FLUCELVAX [®] FLUCELVAX [® ]
H1N1
QIV US
FLUAD [® ] US
Ig
Specialty
Haem
Vaccines
----- End of picture text -----

6 | Driven by Our Promise[™]

Leveraging Global Capabilities

Integration via project management processes

7 | Driven by Our Promise[™]

R&D Portfolio - December 2017

	RESEARCH	PRE-CLINICAL	PHASE I	PHASE II	PHASE III	REGISTRATION	COMMERCIAL / PHASE IV
Life Cycle Management / Market Development	Clinical Applications	C1-INH New Indications			PRIVIGEN® Japan	HIZENTRA® CIDP	PRIVIGEN® CIDPUS
		Fibrinogen New Formulations			HIZENTRA® IIM		KCENTRA® Japan
		Haptoglobin/ Hemopexin		CSL964 AAT GvHD Prevention		CSL830 C1-INHSubcut EU	HAEGARDA® US
		CSL640 rIX-FPsubct			PRIVIGEN® CIDP Japan	AFLURIA® QIV 5-17 AUS	FLUAD® TIV 65+ US, UK
					CSL842 C1-INH AMR		FLUCELAX® QIV 4+US
							AFLURIA® QIV 5-17US

New Product Development	Emerging Technologies	CSL730 rFc Multimer			clazakizumab Transplant*		IDELVION®
	Novel Strategies	CSL626 D’D3 LA rVIII	CSL312 Anti-FXIIa	Mavri GM-CSFR- AZ*	pdFVIII Ruide		AFSTYLA®
	Discovery Projects	CSL334 IL-13R ASLAN*	CSL324 Anti-G-CSF
	Clinical Applications	CSL311 Anti-BC	CSL346 Anti-VEGF-B		CSL112 apo-AI
		P. gingivalis/POD OH-CRC*

*Partnered Projects

8 | Driven by Our Promise[™]

Progress Through Stage Gates in 2018

==> picture [850 x 73] intentionally omitted <==

----- Start of picture text -----

New Product
Phase I Registration & Post
Product Research Development & Phase II Phase III
(FIH) Launch Registration
Opportunity GLP Toxicology
1 2 3 4 5 6 7
----- End of picture text -----

1	2	3		4	5	6	7
Ent Rese	er arch Enter Dev. T	Product & GLP ox. Enter P	hase I Enter	Phase II Enter I	Phase II E Reg & La	nter ister unch Ente Regis	r Post tration
	Emerging Technologies	CSL787 Nebulised Ig	CSL730 rFC Multimer	CSL312 Anti-FXIIa		PRIVIGEN® CIDP Japan	HIZENTRA® CIDP US
	Novel Strategies					HIZENTRA® CIDP Japan	PRIVIGEN® CIDP US
	Clinical Applications						HIZENTRA® CIDP EU
	Clinical Applications	CSL889 Hemopexin in SCD					CSL830 C1-INH Subcut EU
	Discovery Projects	CSL200 (CAL-H) SCD	CSL346 Anti-VEGF-B PhIb				AFLURIA® QIV 6m+ US
		*CSL626 D’D3* *LA rVIII*	CSL324 Anti-GCSF PhIb		CSL112 Apo-AI	AFLURIA® QIV 6m-4 yr AUS	FLUCELAX® QIV 4+ yr US
			CSL334 IL-13R ASLAN*		Pre-Pandemic Vaccine (aH5N1c)	FLUAD® QIV 65+yr US	FLUAD® aTIV 65+ yr US, UK, AUS

9 | Driven by Our Promise[™]

R&D Portfolio - December 2018

	RESEARCH	PRE-CLINICAL	PHASE I	PHASE II	PHASE III	REGISTRATION	COMMERCIAL / PHASE IV
New Product Development	Emerging Technologies	CSL787 Nebulised Ig	CSL730 rFc Multimer	CSL312 Anti-FXIIa in HAE	Clazakizumab Transplant*		IDELVION®
	Novel Strategies	CSL311 Anti-BC	CSL324 Anti-G-CSF	Mavri GM-CSFR*	pdFVIII Ruide		AFSTYLA®
	Discovery Projects	CSL200 (CAL-H) SCD	CSL346 Anti-VEGF-B		CSL112 Apo-AI		FLUAD® aTIV 65+ yr US, UK, AUS
	Haptoglobin	CSL889 Hemopexin in SCD	CSL334 IL-13R ASLAN*		FLUAD QIV 65+ yr		FLUCELAX® QIV 4+ yr US
	Clinical Applications	P. gingivalis/POD OH-CRC*			Pre-Pandemic Vaccine (aH5N1c)		CSL830 C1-INH Subcut EU
Life Cycle Management / Market Development	Clinical Applications	C1-INH New Indications			PRIVIGEN® ID Japan		PRIVIGEN® CIDP US
		Fibrinogen New Formulations			HIZENTRA® IIM	AFLURIA® QIV 6m-4 yr AUS	HIZENTRA® CIDP
					CSL842 C1-INH AMR	PRIVIGEN® CIDP Japan	KCENTRA® Japan
					CSL964 AAT GvHD Prevention	HIZENTRA® CIDP Japan	HAEGARDA® US
							AFLURIA® QIV 6m+ US

Core Capabilities: Immunoglobulins | Haemophilia | Specialty Products | Breakthrough Medicines | Transplant | Vaccines & IP

*Partnered Projects

10 | Driven by Our Promise[™]

Seqirus R&D Dr Gregg Sylvester Vice President Medical Affairs

==> picture [376 x 540] intentionally omitted <==

11 | Driven by Our Promise[™]

Seqirus Influenza Vaccines

==> picture [616 x 326] intentionally omitted <==

----- Start of picture text -----

At-risk
Standard risk populations
seasonal Adjuvanted
TIV / QIV seasonal
TIV / QIV
Pandemic
Cell Based Egg Based
Influenza Science
----- End of picture text -----

==> picture [92 x 52] intentionally omitted <==

12 | Driven by Our Promise[™]

Influenza Viruses Mutate in Various Ways

==> picture [823 x 353] intentionally omitted <==

----- Start of picture text -----

Circulating virus
Yearly seasonal vaccine
Environmental shift Immunological drift
• Environmental 4 strains
•
Manufacturing 2 x “A” – H3N2, H1N1
2 x “B” – B/Victoria, B/Yamagata
New virus Strain altered
Usually vary season to season
→ pandemic → seasonal
•
Southern Hemisphere vs Northern
Hemisphere
----- End of picture text -----

13 | Driven by Our Promise[™]

Seqirus Technologies aim to Enhance Influenza Vaccines

==> picture [516 x 354] intentionally omitted <==

----- Start of picture text -----

Cell Seed Egg Seed
Circulating strain MF59
Adjuvant
Antigenic distance
Antigenic distance
----- End of picture text -----

14 | Driven by Our Promise[™]

Milestones in 2018

AFLURIA QIV
US approval for 6M-4yrs
FLUCELVAX QIV
US approval of major process improvement (“FCC3.0”)
European positive opinion
Positive effectiveness data compared with egg-based vaccines in US 2017-18 season
FLUAD
Completion of US registration QIV trial for 65yrs+
Positive TIV effectiveness data compared with non-adjuvanted vaccines
Pre-Pandemic vaccine (MF59-adjuvanted H5N1 cell = aH5N1c)
Clinical program completed

15 | Driven by Our Promise[™]

Successful completion of AFLURIA QIV program

==> picture [113 x 57] intentionally omitted <==

==> picture [886 x 322] intentionally omitted <==

----- Start of picture text -----

6 to 35 months age group 36 to 59 months age group
NHF0405
USF0629
USF0736
AFLURIA TIV
Pooled
Fluzone
USF0736
Fluzone
AFLURIA
0 5 10 15 20 25 30 35 40 45 50 5 10 15 20 25 30 35 40 45 50
----- End of picture text -----

Percentage of subjects with fever above 38[º] C

16 | Driven by Our Promise[™]

Improvements in FLUCELVAX manufacturing output

Number of doses of FLUCELVAX manufactured by calendar year

==> picture [843 x 329] intentionally omitted <==

----- Start of picture text -----

30
FCC3.0 dossier
filing
• MDV launch
25 • FCC3.0 PPQ
20
15
FCC3.0
Licensed for 2 lines • QIV PFS approval
• TIV PFS • Latex free
10 • 18yr+ indication • 4yr+ indication
Licensed for 1 line
• TIV PFS
5 • 18yr+ indication
0
CY14 CY15 CY16 CY17 CY18
Trivalent (TIV) Quadrivalent (QIV)
million doses
----- End of picture text -----

17 | Driven by Our Promise[™]

Vaccine Seed Adapts to Grow in Eggs

==> picture [446 x 171] intentionally omitted <==

----- Start of picture text -----

Adaptation Required in Generation of Egg Seed
Seasonal strain
\
Selection based on
• seasonal HA and NA
•
high growth properties
----- End of picture text -----

==> picture [153 x 14] intentionally omitted <==

----- Start of picture text -----

High growth donor strain
----- End of picture text -----

==> picture [119 x 80] intentionally omitted <==

No Adaptation Required in Generation of Cell Seed

Seasonal strain

==> picture [54 x 48] intentionally omitted <==

==> picture [62 x 59] intentionally omitted <==

==> picture [116 x 105] intentionally omitted <==

----- Start of picture text -----

High yielding viruses
selected as cell seed
(grown in MDCK)
----- End of picture text -----

==> picture [201 x 125] intentionally omitted <==

18 | Driven by Our Promise[™]

Science describes specific adaptation required for virus to grow in eggs, especially (but not only) H3N2

==> picture [451 x 353] intentionally omitted <==

----- Start of picture text -----

HEMAGGLUTININ
Receptor Dominant
binding Antigenic
site Region
HA1
HA2
----- End of picture text -----

==> picture [375 x 57] intentionally omitted <==

==> picture [109 x 13] intentionally omitted <==

==> picture [107 x 12] intentionally omitted <==

==> picture [330 x 47] intentionally omitted <==

==> picture [187 x 19] intentionally omitted <==

==> picture [284 x 50] intentionally omitted <==

==> picture [76 x 18] intentionally omitted <==

==> picture [75 x 17] intentionally omitted <==

==> picture [307 x 48] intentionally omitted <==

==> picture [177 x 17] intentionally omitted <==

19 | Driven by Our Promise[™]

H3N2-dominant seasons occur often and can be associated with a substantial health burden

==> picture [511 x 322] intentionally omitted <==

----- Start of picture text -----

Deaths 37,000 12,000 43,000 38,000 51,000 25,000 51,000
----- End of picture text -----

==> picture [319 x 322] intentionally omitted <==

Source: US data from CDC , available at www.cdc.gov/flu/about/disease/2015-16.htm

20 | Driven by Our Promise[™]

US 2017-18 Season was Severe and Dominated by H3N2

==> picture [648 x 322] intentionally omitted <==

----- Start of picture text -----

First season a cell-based
seed was included in
FLUCELVAX
→ H3N2 chosen
----- End of picture text -----

Source: Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD); https://www.cdc.gov/flu/weekly/index.htm#OISmap

21 | Driven by Our Promise[™]

Big Data to Assess Real World Health Impact of a Vaccine

Randomised clinical trials provide an estimate of efficacy in a controlled setting in a welldefined population
Real world vaccine effectiveness (VE) evaluation addresses the health impact of a vaccine in the general population
Relative VE – versus another vaccine
Absolute VE – versus no vaccine
We conducted a retrospective cohort study of relative VE assessment of FLUCELVAX™ QUADRIVALENT with H3N2 cell seed versus egg-based vaccines during the 2017/18 season in the USA using Electronic Medical Records (ALLSCRIPTS)

Note: FLUCELVAX[®] Quadrivalent was approved by FDA based upon demonstrated non-inferiority relative to FLUCELVAX[®] trivalent influenza vaccine. There have been no RCT demonstrating clinical superiority compared with egg-based or other influenza vaccines. Real World VE data not for US promotional use.

22 | Driven by Our Promise[™]

Relative VE of cell- vs egg-based vaccines in 2017-18 US Season

Seqirus data (ALLSCRIPTS)*
→ 36% (95% CI 26.1, 44.9) reduction in ‟influenza-like illness”
FDA data (Centers for Medicare & Medicaid Services)^
→ 11% (95% CI 7.5, 13.7) reduction in hospital/ER “encounters”
Nth CA Kaiser Permanente[#]
8% (NS) reduction in influenza A by lab test (PCR)
Boikos et al, Effectiveness of the Cell Culture- and Egg-Derived, Seasonal Influenza Vaccine during the 2017-2018 Northern Hemisphere Influenza Season, US National Foundation for Infectious Disease 2018 Clinical Vaccinology Course, November 2018, (Poster), Bethesda MD
^ Lu et al, Relative effectiveness of cell-cultured versus egg-based influenza vaccines, 2017-18. Advisory Committee on Immunization Practices June 2018. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-06/flu-03-Lu-508.pdf. Accessed 28 October 2018
Klein et al, Vaccine Effectiveness of Flucelvax Relative to IIV During the 2017-18 Influenza Season in Northern CA. IDWeek October 2018, San Francisco, CA (Late Breaker 15).

23 | Driven by Our Promise[™]

Francis Crick Institute (WHO) 15 year data Cell- vs egg-based “reference virus” similarity to wild-type H3N2

Virus collection date

==> picture [640 x 158] intentionally omitted <==

100

Cell-propagated virus; n = < 50 Cell-propagated virus; n = 50 – 99 Cell-propagated virus; n = ≥ 100

Egg-propagated virus; n = < 50 Egg-propagated virus; n = 50 – 99 Egg-propagated virus; n = ≥ 100

Average № isolates: Cell = 90; Egg = 96 * Two vaccine strains in one season † Data values undetermined

Oseltamivir use (20 nM) 40 20 0 † † † † † † †

Antigenically similar if sera demonstrate no more than a 4-fold lower HI reactivity against wild-type compared with reference virus

24 | Driven by Our Promise[™]

MF59 Adjuvant

Oil-in-water adjuvant
Seasonal vaccine (FLUAD) – increased and broader immunogenicity, focussed on people 65yrs and older
Pandemic vaccine – dose sparing

==> picture [216 x 127] intentionally omitted <==

----- Start of picture text -----

Span 85
Tween 80
Squalene
----- End of picture text -----

aH5N1c dose 1/12 of that required without adjuvant
>130 million doses administered – excellent clinical safety

25 | Driven by Our Promise[™]

FLUAD is Gaining Wider Usage for People 65yrs and Older

Approved in Europe 1997, USA 2015
Preferential recommendation for population 65years and older in UK & AUS
Meta-analysis* of published studies (real world data) describes effectiveness of FLUAD in prevention of lab-confirmed influenza and hospitalisation in people 65 years and older

*Domnich et al, Vaccine 35:513-520, 2017

26 | Driven by Our Promise[™]

Real World Data to Investigate the Potential Benefits of FLUAD

FDA/CMS (insurance claims) data 2017/18 season
FLUAD showed 3% reduction in hospital/ER encounters in mismatch season*
Cluster Randomised Trial in Nursing Homes during 2016/17 season (interim analysis)
FLUAD showed 6% reduction in all-cause hospitalisation in mismatch season^
Previous study of similar design by same investigators with Fluzone HD – 6.7% reduction in all-cause hospitalisation in matched season[#]

* Lu et al, Relative effectiveness of cell-cultured versus egg-based influenza vaccines, 2017-18. Advisory Committee on Immunization Practices June 2018. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2018-06/flu-03-Lu-508.pdf. Accessed 28 October 2018

^ Gravenstein et al. A cluster-randomized trial of adjuvanted trivalent influenza vaccine vs. standard dose in U.S. nursing homes. IDWeek October 2018, San Francisco, CA (Poster 996)

# Gravenstein et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. Lancet Respir Med 2017 Sep;5(9):738-746.

27 | Driven by Our Promise[™]

Seqirus Technologies aim to Enhance Influenza Vaccines

==> picture [516 x 354] intentionally omitted <==

----- Start of picture text -----

Cell Seed Egg Seed
Circulating strain MF59
Adjuvant
Antigenic distance
Antigenic distance
----- End of picture text -----

28 | Driven by Our Promise[™]

Anticipated Milestones in 2019

AFLURIA QIV
AUS approval for 6M-4yrs
FLUCELVAX QIV
European approval for 9yrs+
AUS submission

• FLUAD QIV

US approval for 65yrs+
EU/UK and AUS submissions
PrePandemic aH5N1c
US submission

29 | Driven by Our Promise[™]

CSL Behring Research and Early Development Portfolios Dr Andrew Nash Senior Vice President, Research

==> picture [409 x 429] intentionally omitted <==

30 | Driven by Our Promise[™]

Research Organisation and Portfolio

Coordinated global project portfolio

Specialty Breakthrough Products Medicines

Immunoglobulins Haemophilia

Bio21(Parkville), Bern and Marburg
Bio21 expansion completed

==> picture [120 x 160] intentionally omitted <==

Research capabilities: plasma and recombinant proteins, gene and cell-based therapies

==> picture [171 x 128] intentionally omitted <==

Transplant

==> picture [234 x 176] intentionally omitted <==

Bio21 expansion

31 | Driven by Our Promise[™]

Research Organisation and Portfolio

Relocation of CSL Research Bern

Swiss Institute of Translational and Entrepreneurial Medicine (SITEM)

Bern University and Hospital Campus
Translational medicine, Phase I Unit
Cell and Gene Therapy

==> picture [188 x 140] intentionally omitted <==

==> picture [211 x 138] intentionally omitted <==

==> picture [248 x 187] intentionally omitted <==

Bern relocation / expansion – completed by H1 2019

32 | Driven by Our Promise[™]

Early Development Portfolio

• Portfolio of preclinical and early-mid stage clinical opportunities consistent with CSL commercial objectives

• Delivery of high quality candidates for clinical development

Research Product Dev / Tox Phase I Phase II

CSL312 (anti-FXIIa) CSL324 (anti-G-CSF) CSL346 (anti-VEGF-B) CSL730 (rFC multimer) CSL311 (anti-βc) CSL200 (γ-globin gene therapy) CSL787 (nebulised Ig) CSL889 Haemopexin CSL334/ASLAN004* (anti-IL-13Rα1)

partnered, CSL retains significant stake

More detail about our pipeline projects can be found here https://www.csl.com/research-and-development/product-pipeline

33 | Driven by Our Promise[™]

Immunoglobulin Therapy

==> picture [863 x 322] intentionally omitted <==

----- Start of picture text -----

Ig Fab region
• Immune deficiencies
• Autoimmune conditions
recombinant Fc multimer – CSL730
FcRn
Ig Fc region targeting
Potentially reproduces all
• Autoimmune conditions
Fc mediated Ig activity
FcγR
targeting
----- End of picture text -----

From Lunemann et al ., Nat Rev Immunol 2015

34 | Driven by Our Promise[™]

Immunoglobulin Therapy

Targeting FcRn – IG vs. anti-FcRn agents

IV & SC IG therapy in autoimmune disease
Increase in total circulating IgG
Pathogenic auto-antibody IgG out-competed for access to FcRn
Long term safety established

Anti-FcRn therapy

Relevant for auto-antibody mediated disease only
Blocks access of all IgG to FcRn
Total circulating IgG reduced by up to 80%
Long term safety implications unclear

==> picture [392 x 351] intentionally omitted <==

----- Start of picture text -----

IVIG therapy
FcRn recycling controls
circulating levels of IgG
Ab mediated auto-immunity
Anti-FcRn therapy
= pathogenic auto-antibody
----- End of picture text -----

35 | Driven by Our Promise[™]

Immunoglobulin Therapy

Mechanism of action summary

==> picture [826 x 313] intentionally omitted <==

----- Start of picture text -----

Pathogen Reduction of Complement FcγR Expression Immune Cells Cytokine
Neutralisation Pathologic Ig Scavenging Modulation Modulation Modulation
Ig Therapy
IgG Fc
Multimers
FcRn Binding Agents
No Activity Possible Activity Activity
----- End of picture text -----

36 | Driven by Our Promise[™]

CSL730 – Recombinant Fc Multimer

CSL730 is effective in a mouse model of ITP CSL730 dose

Non-clinical safety toxicity data supports commencement of FIH studies
Phase I study (healthy volunteers) commenced Q1 2018

37 | Driven by Our Promise[™]

Immunoglobulin Therapy – Expanding Benefit

Nebulised Ig – respiratory tract infections

Concept: Prevention of viral and bacterial infections of the respiratory tract by inhaling polyclonal immunoglobulins
Technical feasibility demonstrated

Potential indications for NebIg:

==> picture [329 x 197] intentionally omitted <==

Prevention of infections in PID patients
Prevention of infection-related exacerbations in COPD and Bronchiectasis patients

38 | Driven by Our Promise[™]

Immunoglobulin Therapy – Expanding Benefit

Inhaled IgG prevents bacterial and viral infection

==> picture [409 x 284] intentionally omitted <==

----- Start of picture text -----

Mouse model of S. pneumoniae infection
100
50
Vehicle
IgG
0
0 5 10 15 20 25
Days
Intranasal IgG prevents S. pneumonia
bacterial infection in mouse model
Percent survival
----- End of picture text -----

==> picture [408 x 284] intentionally omitted <==

----- Start of picture text -----

In vitro model of influenza virus infection
Tissue integrity Mucociliary clearance
infected infected
IgG preserves tissue integrity and mucociliary clearance of
primary human bronchial cells after influenza virus infection
----- End of picture text -----

GLP Toxicology studies in progress
First-in-human trial planned for 2019

39 | Driven by Our Promise[™]

CSL312 – HAE and Thrombosis

• Targeting FXIIa represents a novel approach to the treatment of HAE & contact activated thrombosis

Efficacy in multiple animal models and translational studies

==> picture [555 x 298] intentionally omitted <==

----- Start of picture text -----

Auto-activation
FXIIa -
FXI → FXIa PK → KAL βFXIIa
→ thrombin HK → BK→ BR2 C1qr,s → C1qr,s
Vasodilation, Complement
Haemostasis
vascular permeability activation
Thrombosis HAE Transplant
----- End of picture text -----

40 | Driven by Our Promise[™]

CSL312 – HAE and Thrombosis

First in Human (healthy volunteers) Phase I study

==> picture [597 x 262] intentionally omitted <==

----- Start of picture text -----

Pharmacokinetics (SAD)
•
Phase II study in HAE
patients in progress
•
Study in contact activated
thrombosis to commence
in 2019
Time (h)
CSL312 serum conc.(mg/ml)
----- End of picture text -----

Safe and well tolerated
Linear pharmacokinetics with expected pharmacodynamic effects
Inhibits FXIIa mediated activity in a dose dependent manner

41 | Driven by Our Promise[™]

CSL324 – Neutrophil Mediated Inflammation

G-CSF / Neutrophils / Inflammation

Neutrophils – contribute to protective mechanism against infections
Neutrophil numbers and activity under control of Granulocyte Colony Stimulating Factor (G-CSF)
Excessive activated neutrophils can cause chronic severe inflammatory diseases
Targeting G-CSF represents a novel approach to the treatment of inflammatory diseases
Efficacy in multiple animal models and translational studies

==> picture [468 x 335] intentionally omitted <==

----- Start of picture text -----

COPD exacerbations
CF exacerbations
ARDS
Reperfusion injury /
Delayed graft function
Rheumatoid
arthritis
G-CSF
Vasculitis
Neutrophilic
dermatoses
----- End of picture text -----

42 | Driven by Our Promise[™]

CSL324 – Neutrophil Mediated Inflammation

First in Human (healthy volunteers) Phase I study

==> picture [370 x 262] intentionally omitted <==

----- Start of picture text -----

Pharmacokinetics (SAD)
10
0.8 mg/kg
1.0
0.3 mg/kg
0.1 mg/kg
0.1
Nominal time
CSL334 serum conc.(mg/ml)
----- End of picture text -----

Safe and well tolerated
Linear PK with target saturation and expected pharmacodynamic effects
ex vivo STAT 3 and in vivo G-CSF challenge

43 | Driven by Our Promise[™]

CSL324 – Neutrophil Mediated Inflammation

Phase Ib study in neutrophilic dermatoses commencing Q2 2019

Hidradenitis Suppurativa (Acne Inversa)

Palmoplantar pustulosis

Chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle
Characterised by a chronic eruption of sterile pustules on palms and soles – filled with neutrophils
Lesions are painful, unsightly, odorous, with devastating effect on the patients QOL
Prevalence 1-4% of the general population

==> picture [87 x 133] intentionally omitted <==

Unmet need – Adalimumab is not effective in all patients, and does not always have a durable response
The lesions are usually painful and decrease patients QOL
Prevalence data limited – very rare
Unmet need – SoC topical steroids, phototherapy and systemic Methotrexate, cyclosporine

==> picture [166 x 80] intentionally omitted <==

44 | Driven by Our Promise[™]

CSL324 – Neutrophil Mediated Inflammation

Kidney graft reperfusion injury

G-CSFR blockade protects against renal Ischemia Reperfusion Injury (IRI) in a mouse model

==> picture [836 x 285] intentionally omitted <==

----- Start of picture text -----

G-CSFR blockade prevents neutrophil infiltration
Control Ab (500 ug) VR81 (100 ug)
Left renal
ischemia (22 min)
20 µm
Reperfusion
for 24 hours
VR81 = surrogate anti-mG-CSFR
Ly-6G
----- End of picture text -----

45 | Driven by Our Promise[™]

CSL324 – Neutrophil Mediated Inflammation

Kidney graft reperfusion injury

G-CSFR blockade protects against renal IRI in a mouse model

==> picture [704 x 268] intentionally omitted <==

----- Start of picture text -----

G-CSFR blockade preserves kidney function
VR81 = surrogate anti-mG-CSFR
----- End of picture text -----

Opportunity for CSL324 in solid organ transplantation

46 | Driven by Our Promise[™]

Research and Early Development

Expanding capacity and capability across global Research sites
New projects leveraging Calimmune gene and cell therapy technologies
Continuing to innovate in areas of business strength

Specialty Immunoglobulins Haemophilia Products

Developing new opportunities in areas of unmet need

Breakthrough Medicines

Transplant

Creating and progressing a sustainable portfolio of early stage opportunities

47 | Driven by Our Promise[™]

Commercial Market Overview

Mr Bill Campbell Executive Vice President & Chief Commercial Officer

==> picture [409 x 429] intentionally omitted <==

48 | Driven by Our Promise[™]

Targeted Protein Therapeutic Market

==> picture [487 x 328] intentionally omitted <==

----- Start of picture text -----

Albumin
$4.1B
Immunoglobulin
$11.1B
Total Global
Market Value:
~$30.5B
Haemophilia
$11.4B
Specialty
$3.6B
----- End of picture text -----

Source: Adivo, Global Market Research, Analyst Reports, Company Annual Reports, Haemophilia mkt includes Inhibitor mkt

49 | Driven by Our Promise[™]

CSL Portfolio

==> picture [390 x 380] intentionally omitted <==

----- Start of picture text -----

Albumin Immunoglobulin
Haemophilia
Specialty
----- End of picture text -----

CSL Total FY18 $6,678M $3,145M +11% $1,490M +24% $1,113M +5% $921M +7% Growth at constant currency

50 | Driven by Our Promise[™]

New Product Launches

==> picture [143 x 60] intentionally omitted <==

==> picture [130 x 64] intentionally omitted <==

==> picture [151 x 65] intentionally omitted <==

==> picture [133 x 58] intentionally omitted <==

==> picture [93 x 56] intentionally omitted <==

==> picture [836 x 50] intentionally omitted <==

----- Start of picture text -----

CIDP CIDP
March ‘16 May ‘16 June ‘17 Feb. ’18 March ‘18
(US only)
----- End of picture text -----

Launch date denotes first country to launch globally

5 major launches in 24 months Some of the most successful launches in the industry Significant contribution to the business now…in future

R&D Productivity

Commercial Excellence

51 | Driven by Our Promise[™]

Immunoglobulin Market

Global IG volume by indication 9% Growth

==> picture [268 x 267] intentionally omitted <==

----- Start of picture text -----

PID
28%
Other
21%
MG
4%
ITP
6%
CIDP
24%
SID
17%
----- End of picture text -----

Growth Drivers

Enhanced diagnosis in PID, CIDP
Immunotherapy driving SID growth
Increasing per capita use in emerging markets
• Continued market supply tightness

Source: Data on file

52 | Driven by Our Promise[™]

==> picture [144 x 36] intentionally omitted <==

CSL Portfolio: Immunoglobulin

==> picture [352 x 357] intentionally omitted <==

----- Start of picture text -----

Immunoglobulin
Albumin
Haemophilia
Specialty
----- End of picture text -----

FY18 $3,145M +11%

==> picture [251 x 18] intentionally omitted <==

----- Start of picture text -----

•
Above market volume growth
----- End of picture text -----

Expansion in PID, SID, CIDP
Balanced growth across all regions
Continued life-cycle investments Disciplined execution

53 | Driven by Our Promise[™]

Immunoglobulins: Category Leadership

==> picture [108 x 123] intentionally omitted <==

GROW

the current business

EXPAND

our presence in neurology

INNOVATE

and protect the franchise

Maximise PID / SID opportunity
Leverage broad portfolio

• Enhance product offerings

Replicate our approach to build market leading segments
Build on PRIVIGEN[®] experience in CIDP
Launch HIZENTRA[®] in CIDP
Novel delivery devices
New indications e.g. IIM, SSc
rFc multimer

54 | Driven by Our Promise[™]

==> picture [46 x 40] intentionally omitted <==

==> picture [159 x 41] intentionally omitted <==

==> picture [567 x 207] intentionally omitted <==

----- Start of picture text -----

Privigen is a ready-to-use Proven effective and well
10% IVIG approved in tolerated with
80+ countries 10+ years
worldwide [1] of patient experience
Approved for use in Used in Proven efficacy and
tolerability profile since
6 >100,000 patients
indications 2010
with chronic disease in the last year [2]
----- End of picture text -----*

==> picture [251 x 184] intentionally omitted <==

----- Start of picture text -----

More than
100,000
patient-years of & 6 million
experience [3] exposures worldwide [3]
57 countries
HIZENTRA [®] is a 20% SCIG that is
approved in 57 countries worldwide [4]
----- End of picture text -----

References: 1. Data on file. Available from CSL Behring as PRI-10015; 2. Data on file. Available from CSL Behring as DOF-PRI-10016; 3. Data on file. Available from CSL Behring as DOF-HIZ-005; 4. Data on file. Available from CSL Behring as DOF-HIZ-004

*PID,SID, adults with CIDP, chronic ITP, Guillain-Barre syndrome and Kawasaki disease All Indications are not approved in all markets

55 | Driven by Our Promise[™]

: Innovator, Market Leader

==> picture [397 x 284] intentionally omitted <==

----- Start of picture text -----

Patients on SCIG Therapy: US 1
16,000
14,000
12,000
10,000
8,000
6,000
4,000
2,000
0
Q1'16 Q2'16 Q3'16 Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18
Cuvitru Competitor 1 HIZENTRA® HyQvia Competitor 2
----- End of picture text -----

==> picture [396 x 284] intentionally omitted <==

----- Start of picture text -----

Patients on SCIG Therapy: 7 Major Markets 1
25,000
20,000
15,000
10,000
5,000
0
Q1'16 Q2'16 Q3'16 Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18 Q2'18
Cuvitru Competitor 1 HIZENTRA® HyQvia Competitor 2
----- End of picture text -----

Source: Adivo Q2 2018 Tracking Data Major Markets include: US, Germany, France, Spain, Italy, UK, Japan 1 Not all products shown

56 | Driven by Our Promise[™]

addresses unmet needs in CIDP therapy

CIDP Update

Early in launch cycle
Leading indicators are positive
Market share growth with both PRIVIGEN[®] and HIZENTRA[®]

Significant opportunity for leadership with HIZENTRA[®]

==> picture [466 x 313] intentionally omitted <==

----- Start of picture text -----

5x as many patients
Experience IV- said they felt fewer Have venous HIZENTRA [®]
related systemic side effects with access issues does not require
adverse reactions venous access
HIZENTRA [®]
8x as many patients HIZENTRA [®] provides
Seek the flexibility, Require more
said HIZENTRA [®] steady state Ig levels
freedom, and control frequent infusions to
offers more freedom for continuous
of self-infusing manage their disease
than IVIG control
----- End of picture text -----

Source: Data represents patients reporting a preference between IVIG in the prerandomized phase and Hizentra in the randomized phase of the phase III study of subcutaneous immunoglobulin for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) – the PATH study

57 | Driven by Our Promise[™]

==> picture [497 x 383] intentionally omitted <==

Positioned for continued growth
Expanding market presence
Diverse disease opportunities
Balanced geographic footprint
Continued life cycle investment
Plasma collections running ahead of the market
Early days…but very positive in CIDP

Market Leading Therapies

58 | Driven by Our Promise[™]

Haemophilia Market

==> picture [315 x 313] intentionally omitted <==

----- Start of picture text -----

Inhibitor
20%
VWD
4%
Total value
$11.4B
Hem B Hem A
14% 62%
----- End of picture text -----

Highly competitive Haem A segment
Rapid transition of Haem B to long acting products
75% of patients with bleeding disorders are under or untreated
New technologies / advancements hold great promise…

59 | Driven by Our Promise[™]

CSL Portfolio: Haemophilia

==> picture [328 x 357] intentionally omitted <==

----- Start of picture text -----

Albumin
Immunoglobulin
Haemophilia
Specialty
----- End of picture text -----

==> picture [120 x 26] intentionally omitted <==

==> picture [118 x 38] intentionally omitted <==

==> picture [113 x 32] intentionally omitted <==

==> picture [123 x 63] intentionally omitted <==

FY18 $1,113M +5%

Haem A

AFSYTLA[®]
- Launched in 12 countries
Plasma-derived portfolio
Haem B
IDELVION[®]
- Transformational Product
- Strong growth
- Market leadership

von Willebrand Disease

HUMATE-P[®] , VONCENTO[®]
Strong contributors to portfolio

60 | Driven by Our Promise[™]

Positioning in a Competitive Market

Higher binding affinity to vWF	• Unique single-chain molecular structure provides increased binding • Enhanced binding affinity protects AFSTYLA® from degradation, extending time in circulation
2x weekly dosing	• FDA-approved for 2x or 3x weekly dosing • Factor trough levels above 1.9% with 2x weekly dosing
Excellent bleed protection	• ZERO bleeds (median AsBR*) in all patients, regardless of age and dosing frequency
Low annual consumption	• AFSTYLA® delivers the benefits of an EHL† with the lowest annual consumption

AsBR: Annualized spontaneous bleeding rate.
EHL: Extended half life

61 | Driven by Our Promise[™]

==> picture [184 x 57] intentionally omitted <==

Clinical Profile is Uniquely Differentiated

==> picture [317 x 329] intentionally omitted <==

0 • Zero median annualized spontaneous
Median AsBR bleeding rate (AsBR) in prophylaxis
Up to 14 day dosing • Greater freedom from infusions 21% Factor IX* • High and sustained factor levels at
steady state trough levels[†] steady-state with prophylactic use • IDELVION is the most switched
#1 Factor Choice[1] to Factor IX when changing therapy
In appropriate patients 12 years and older.
Average FIX levels with 7-day dosing over 92 weeks in clinical trials Reference: 1. Data on file. Available from CSL Behring as DOF IDL-002.

62 | Driven by Our Promise[™]

==> picture [194 x 61] intentionally omitted <==

Performance in Key Markets

==> picture [408 x 174] intentionally omitted <==

----- Start of picture text -----

Switzerland
100%
80%
58%
60%
40%
20%
0%
Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18
----- End of picture text -----

==> picture [407 x 174] intentionally omitted <==

----- Start of picture text -----

Germany
100%
80%
58%
60%
40%
20%
0%
Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18
----- End of picture text -----

==> picture [408 x 174] intentionally omitted <==

----- Start of picture text -----

Japan
60%
50%
40% 37%
30%
20%
10%
0%
Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18
----- End of picture text -----

==> picture [407 x 174] intentionally omitted <==

----- Start of picture text -----

US
50%
40%
30%
30%
20%
10%
0%
Q1 16 Q2 16 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18
----- End of picture text -----

Source: Adivo Q2 2018 Tracking Data Patient share of recombinant prophylaxis in launch markets

IDELVION[®] ALPROLIXCompetitor 1[®]

Competitor 2BeneFIX[®] All Other

63 | Driven by Our Promise[™]

Q&A

==> picture [409 x 429] intentionally omitted <==

64 | Driven by Our Promise[™]

Clinical Development Dr Bill Mezzanotte EVP & Head R&D

==> picture [409 x 429] intentionally omitted <==

65 | Driven by Our Promise[™]

Immunoglobulins

==> picture [360 x 322] intentionally omitted <==

----- Start of picture text -----

Breakthrough
Transplant
Medicines
Specialty
Immunoglobulins
Products
Haemophilia
Products
----- End of picture text -----

Maintaining leadership position through focus on:
New Indications
Geographic expansion
Delivery options
Key Focus:
HIZENTRA[®]
PRIVIGEN[®]

66 | Driven by Our Promise[™]

Milestones in Ig Development for CIDP

PRIMA study shows PATH study confirms efficacy of PRIVIGEN[®] efficacy of PRIVIGEN[®] for CIDP for CIDP

HIZENTRA[®] and PRIVIGEN[® ] for CIDP PMDA Approval 2019

==> picture [921 x 186] intentionally omitted <==

----- Start of picture text -----

PRIVIGEN [®] for CIDP PRIVIGEN [®] for CIDP:
approved in EU FDA approval Sept 13
2012 2013 2014 2015 2016 2017 2018 2019
----- End of picture text -----

PATH study confirms HIZENTRA[®] for efficacy of HIZENTRA[®] CIDP FDA & EU for CIDP Approval March 2018

67 | Driven by Our Promise[™]

Impact of Ig (IV & SC) in Rare Diseases

==> picture [763 x 299] intentionally omitted <==

----- Start of picture text -----

Primary
Immuno-
deficiency
Secondary
Additional
Immuno-
Diseases
deficiency
Ig
Immune &
Chronic Inflammatory
Inflammatory Myositis IIM and SSc CIDP
Demyelinating Polyneuropathy
and Systemic Sclerosis
----- End of picture text -----

Health Authority (FDA, EMEA, PMDA) interactions – 2018
• Trials start 2019

| Driven by Our Promise[™]

Haemophilia Products

==> picture [360 x 322] intentionally omitted <==

----- Start of picture text -----

Breakthrough
Transplant
Medicines
Specialty
Immunoglobulins
Products
Haemophilia
Products
----- End of picture text -----

Supporting and enhancing plasma products and developing novel recombinant portfolio with focus on:
Scientific and product innovation
Patient benefit
Key Focus:
IDELVION[®] (rIX-FP)
AFSTYLA[®] (rVIII-Single Chain)

69 | Driven by Our Promise[™]

IDELVION[®] Delivering in the Real World

Annualised Bleed Rates in switched patients

FIX product	All FIX	rFIX-Fc	IDELVION
Prophylaxis-to- prophylaxis patients mean ± SD	7.4 ± 9.1 (n=34)	8.9 ± 9.6 (n=12)	1.5 ± 4.5 (n=34)
# with zero bleed (%)	6 (17.6)	2 (16.7)	23 (67.6)

Further increased dosing flexibility anticipated
21-day dosing submission planned 3Q 19

Escobar et al, ISTH July 2018

85% of All-FIX therapies were administered every 7 days or more frequently
45% of IDELVION administration was every 14 days

70 | Driven by Our Promise[™]

Specialty Products

==> picture [360 x 322] intentionally omitted <==

----- Start of picture text -----

Breakthrough
Transplant
Medicines
Specialty
Immunoglobulins
Products
Haemophilia
Products
----- End of picture text -----

Leveraging high quality broad product portfolio through:
New markets
Novel indications
Novel modes of administration
Key Focus:
HAEGARDA[®] /BERINERT[®]
KCENTRA[®] /BERIPLEX[®]
ZEMAIRA[®] /RESPREEZA[®]

71 | Driven by Our Promise[™]

Hereditary Angioedema (HAE)

Hereditary angioedema (HAE) is a disorder that results in recurrent attacks of severe swelling
All body sites are associated with impairment and patients are impacted during and between attacks
Most severe are laryngeal attacks which can require emergency interventions to protect the airway

==> picture [414 x 299] intentionally omitted <==

72 | Driven by Our Promise[™]

Demonstrating Unique Benefit of HAEGARDA[®]

==> picture [185 x 33] intentionally omitted <==

==> picture [838 x 202] intentionally omitted <==

----- Start of picture text -----

BASELINE Median Attack Rate Reduction: 95%
4
Mean Age 39.6 ± 14.9
3
Female % 67
2
Mean # HAE attacks 3 prior months 9.8 ± 6.6
1
% use of HAE Prophylaxis 3 prior
months 42% 0 Placebo 60 IU/kg
HAE attack/month (median)
----- End of picture text -----

Longhurst et al NEJM March 2017

73 | Driven by Our Promise[™]

Demonstrating Unique Benefit of HAEGARDA[®]

==> picture [185 x 33] intentionally omitted <==

==> picture [421 x 187] intentionally omitted <==

----- Start of picture text -----

CSL830 Reduces Severity of Attacks
100
8.9
75 28.9
Severe
68.9
Moderate
17.8
50
Mild
4.4
Unknown severity
25 No attack
40.0 22.2
2.2
6.7
0
60 IU/kg CSL830 Low-volume Placebo
----- End of picture text -----

==> picture [423 x 187] intentionally omitted <==

----- Start of picture text -----

Persistent Efficacy of 60 IU/Kg
100
90
80
70
60
50 Attack-Free
40 No Rescue Use
30
20
10
0
Months 1-6 Months 13-18 Months 25-30
% of Study Patients
----- End of picture text -----

Longhurst et al NEJM March 2017

74 | Driven by Our Promise[™]

CSL312 Anti-FXIIa in HAE

==> picture [360 x 93] intentionally omitted <==

==> picture [672 x 266] intentionally omitted <==

----- Start of picture text -----

Placebo
Run-in
Low dose
Patients
with HAE
Medium dose
High dose
•
Phase II study
----- End of picture text -----

Phase II study initiated in October

==> picture [87 x 15] intentionally omitted <==

----- Start of picture text -----

Extension
----- End of picture text -----

==> picture [131 x 54] intentionally omitted <==

75 | Driven by Our Promise[™]

Transplant

==> picture [360 x 322] intentionally omitted <==

----- Start of picture text -----

Breakthrough
Transplant
Medicines
Specialty
Immunoglobulins
Products
Haemophilia
Products
----- End of picture text -----

Developing CSL and other novel therapies with potential to improve transplant outcomes:
Significant unmet need
Key Focus:
C1 inhibitor (C1-INH)
Alpha1 anti-trypsin (AAT)
Anti-IL-6 / clazakizumab*

76 | Driven by Our Promise[™]

Solid Organ Transplant (SOT): Unmet Medical Need

==> picture [415 x 33] intentionally omitted <==

----- Start of picture text -----

Before Transplantation
----- End of picture text -----

During Transplantation After Transplantation

==> picture [840 x 201] intentionally omitted <==

----- Start of picture text -----

Patient & Donor Donor Organs Patient Patient
Organ Availability and Organ Viability and Ischemia-Reperfusion Transplant
Patient-Donor Matching Donor Management Injury and Consequences Rejection
Reducing IR-related injury and its
Donor-specific antibody
Decreasing organ discard consequences – e.g. Primary Graft Improving Treatment of
reduction; increased access
and reduce ischemic injury Dysfunction (PGD) & Delayed Antibody Mediated Rejection
to transplantation
Graft Function (DGF)
----- End of picture text -----

More Patients/Organs Viable

==> picture [142 x 40] intentionally omitted <==

----- Start of picture text -----

Graft Survival
----- End of picture text -----

77 | Driven by Our Promise[™]

Improving Graft Survival in Kidney Transplantation

Ischemia-Reperfusion Injury and Consequences

Delayed Graft Function (DGF)

Delayed graft function (DGF - any use of HD within 7 days of KTx or slow graft function (SGF) occurs in 20-30% of cases
More common with deceased donors
Patients who develop DGF have:
~40% increased risk of graft loss and acute rejection
Higher health care costs

==> picture [532 x 330] intentionally omitted <==

----- Start of picture text -----

Transplants by Organ Type
(US - 2015) Transplant Rejection
Other
3%
Antibody Mediated Rejection
Lungs
7%
Heart
9%
•
AMR occurs in up to 5-10% of
transplants acutely and up to
30% chronically
Liver Kidney • AMR is marked by declining renal
58%
23% function and is associated with
lower graft survival
•
Patients with donor-specific
antibodies are denied transplant
due to the risk for AMR
----- End of picture text -----

78 | Driven by Our Promise[™]

Donor-specific Antibodies (DSAs) underpin Antibody Mediated Rejection in Kidney Transplantation

==> picture [428 x 257] intentionally omitted <==

Complement-binding DSAs

Associated with more severe inflammation and graft injury
C1-INH offers therapeutic option

Non-complement-binding DSAs

Antibody-mediated cellular toxicity
Direct endothelial activation & proliferation
Anti IL-6 offers therapeutic option

Loupy A, Lefaucheur C, et al. N Engl J Med . 2013;369(13):1215-1226

79 | Driven by Our Promise[™]

Long Term C1 INH Administration Stabilises Graft Function in AMR Patients Unresponsive to Standard of Care

==> picture [244 x 256] intentionally omitted <==

Renal Function at the time of initial AMR Dx. Renal Function at the end of first-line AMR SOC.

Renal Function at the end of 6 mos. C1inh Tx.

In a pilot study 6 patients with AMR, unresponsive to standard of care, were treated with C1 INH and had improved renal function (estimated Glomerular Filtration Rate, eGFR) at 6 months

Viglietti et al., Am J of Transplantation 2016

80 | Driven by Our Promise[™]

CSL842 Phase III Randomised, Placebo-controlled Withdrawal

==> picture [258 x 98] intentionally omitted <==

==> picture [828 x 308] intentionally omitted <==

----- Start of picture text -----

Part 1: 12 Weeks Part 2: 26 Weeks 3.5 Years
C1 INH
IVIg + C1 INH
open label
Placebo
Responders Randomised 1° endpoint 2° endpoint
Study actively recruiting and on track
Loss of Response Graft Survival
----- End of picture text -----**

**occurrence of any of the following Decline in renal function (eGFR) Allograft failure Subject death

81 | Driven by Our Promise[™]

Vitaeris and CSL Strategic Collaboration in AMR

Clazakizumab (anti-IL6) in clinical development
Successful FDA Type C meeting
Anticipated dosing in chronic AMR patients in 2019
IL-6 may play a role in
DSA production and DSA mediated allograft injury
Cell-mediated rejection

==> picture [167 x 105] intentionally omitted <==

Chronic allograft vasculopathy
Pilot study demonstrated blocking IL-6 stabilises renal function and prolongs graft survival*

*Choi et al Am J Transplantation 2017

82 | Driven by Our Promise[™]

Beyond Solid Organ Transplant: Hematopoietic Stem Cell Transplant (HSCT) and Graft versus Host Disease

==> picture [208 x 15] intentionally omitted <==

----- Start of picture text -----

Annual HSCTs in the US
----- End of picture text -----

==> picture [366 x 188] intentionally omitted <==

==> picture [361 x 183] intentionally omitted <==

GvHD is a common cause of morbidity and mortality in HSCT

~50-60% of Allogeneic HSCT develop acute Graft versus Host Disease (GvHD[) ]
Survival is 30% for Grade III and 10% for Grade IV
Therapies are often ineffective or cause severe immunosuppression

83 | Driven by Our Promise[™]

Potential Immunomodulation of Alpha-1 Antitrypsin (AAT) in Acute GVHD

==> picture [694 x 374] intentionally omitted <==

----- Start of picture text -----

AAT
Cyclosporine or
Tacrolimus + MTX
DAMPs
Activation and
proliferation of
Teff cells
Naïve T cell
PAMPs APC
TNF-α, IL-1β
Acute GVHD
AAT IL-6, IL-32 Teff End-organ damage:
Skin, liver, gut
AAT
Promotion
AAT
Inhibition Treg
Blazar, B. R., et al. (2012). Nat Rev Immunol 12(6): 443-458.
3 : 274 Neutrophil
----- End of picture text -----

Blazar, B. R., et al. (2012). Nat Rev Immunol 12(6): 443-458. Schmidt, S. V., et al. (2012) Front Immunol 3 : 274

84 | Driven by Our Promise[™]

Treatment of Steroid-Refractory GvHD with AAT

==> picture [477 x 194] intentionally omitted <==

----- Start of picture text -----

Mangenau et al Blood 2018
----- End of picture text -----

Alpha-1 Antitrypsin (AAT)

40 Patients with Steroid refractory aGVHD

CSL964 AAT GvHD Prevention

  - Planned evaluations in prophylaxis of GvHD with AAT

  - Study start up activities commenced

Open label AAT - 60mg/kg twice weekly x 4 weeks
Day 28 overall response rate (ORR) - 65%
35% Complete Response
Sustained responses - 73% at Day 60
Well tolerated with low rates of infection

85 | Driven by Our Promise[™]

Breakthrough Medicines

==> picture [360 x 322] intentionally omitted <==

----- Start of picture text -----

Breakthrough
Transplant
Medicines
Specialty
Immunoglobulins
Products
Haemophilia
Products
----- End of picture text -----

Leveraging clinical and technical insight in developing novel proteinbased therapies:
Significant unmet need
Multiple indications

• Key Focus:

CSL112 (ApoA-I)
CSL312 (anti-FXIIa mAb)
CSL324 (anti-G-CSFR mAb)
CSL346 (anti-VEGF-B mAb)
CSL311 (anti-BC mAb)

86 | Driven by Our Promise[™]

CSL112 Hypothesis

CSL112 will

be safe and well tolerated
enhance cholesterol efflux capacity (CEC)
acutely stabilise atherosclerotic plaques and prevent subsequent major adverse cardiovascular events (MACE) in the early, highest risk period (unique treatment period)

==> picture [492 x 313] intentionally omitted <==

----- Start of picture text -----

CSL112
particles
ABCA1 transporter
Intracellular
cholesterol
----- End of picture text -----

87 | Driven by Our Promise[™]

CSL112 Phase III Study Design

==> picture [200 x 87] intentionally omitted <==

==> picture [828 x 165] intentionally omitted <==

----- Start of picture text -----

1° Endpoint: MACE MACE Follow Up
D90 D180 D365
17400 AMI subjects ≥ 18
Placebo (n=8700)
years of age, With Acute Screening Randomisation
6g CSL112 (n=8700)
Coronary Syndrome
1000 Centers - >40 Countries
----- End of picture text -----

Enriched Study Population: Multi-vessel coronary artery disease and at least one of the following:
Age >65
History of MI
Diabetes mellitus
Peripheral artery disease (PAD)
Registry data confirms enriched AEGIS-II population is associated with high early recurrent event rate and supports our trial assumptions

88 | Driven by Our Promise[™]

CSL112 Program Timeline

==> picture [830 x 291] intentionally omitted <==

----- Start of picture text -----

2016 2017 2018 2019 2020 2021 2022 2023
CSL112 CMC - Supply
AEGIS-I
Phase III (AEGIS II) Outcomes Study
BLA
MOD RI Phase II
Futility #1
Mar ‘20
Futility #2 MAA
Oct ‘20
Interim Efficacy
Apr‘21
----- End of picture text -----

Actively recruiting and on track
To date, patient activity at sites supports the Registry data

| Driven by Our Promise[™]

Commercial Overview Specialty, Transplant, CSL112 Mr Bill Campbell Executive Vice President & Chief Commercial Officer

==> picture [409 x 429] intentionally omitted <==

90 | Driven by Our Promise[™]

CSL Portfolio: Specialty

==> picture [307 x 357] intentionally omitted <==

----- Start of picture text -----

Albumin
Immunoglobulin
Haemophilia
Specialty
----- End of picture text -----

FY18 1,490M +24%

==> picture [165 x 70] intentionally omitted <==

==> picture [165 x 54] intentionally omitted <==

==> picture [147 x 63] intentionally omitted <==

==> picture [155 x 48] intentionally omitted <==

==> picture [150 x 39] intentionally omitted <==

==> picture [159 x 38] intentionally omitted <==

91 | Driven by Our Promise[™]

Continued Growth Opportunity for

==> picture [177 x 37] intentionally omitted <==

==> picture [184 x 15] intentionally omitted <==

----- Start of picture text -----

Anticoagulation Market US [1]
----- End of picture text -----

==> picture [258 x 250] intentionally omitted <==

----- Start of picture text -----

Other , 3%
Xarelto, 24%
Warfarin,
39%
Eliquis, 34%
----- End of picture text -----

Warfarin Market US[1]

==> picture [236 x 244] intentionally omitted <==

----- Start of picture text -----

KCENTRA®,
40%
FFP &
Others, 60%
----- End of picture text -----

US clinical practice guidelines recommend KCENTRA[®] over FFP to reverse the effects of Warfarin*

Source: 1. IQVIA NPA Market Dynamics Anti-Coagulant Patients Q3 2018

*Neurocritical Care Society, Society of Critical Care Medicine, American College of Cardiology, American College of Chest Physicians, American Society of Gastrointestinal Endoscopy, American College of Surgeons

92 | Driven by Our Promise[™]

==> picture [177 x 37] intentionally omitted <==

Growth Since Launch

==> picture [306 x 138] intentionally omitted <==

==> picture [460 x 306] intentionally omitted <==

----- Start of picture text -----

End User Demand (IU)
250
200
150
100
50
0
FY 13/14 FY 14/15 FY 15/16 FY 16/17 FY 17/18
Millions
----- End of picture text -----

93 | Driven by Our Promise[™]

Specialty Products –

==> picture [459 x 280] intentionally omitted <==

Transformational HAE therapy
New patients weekly
Strong patient, physician and prescriber engagement
Natural C1 replacement
#1 prescribed therapy in the US for prevention of HAE attacks

94 | Driven by Our Promise[™]

==> picture [122 x 122] intentionally omitted <==

==> picture [186 x 102] intentionally omitted <==

==> picture [187 x 107] intentionally omitted <==

Established efficacy

95% reduction in HAE attacks
Rescue medication reduced by >99%
HAEGARDA[®] studied in patients with 3.8 attacks per month

C-INH for C1-INH deficiency

HAEGARDA[®] replaces missing or dysfunctional C1-INH, regulating the normal production of bradykinin
C1-INH has been used in HAE for over 35 years
WAO Guidelines
2017 WAO Treatment Guidelines recommend the use of C1-INH for first line, long-term prophylaxis therapy

95 | Driven by Our Promise[™]

Why

Key KOL Quote

“With efficacy it is as good as it gets with HAEGARDA[®] . However if Lanadelumab can prove the same level of efficacy, HAEGARDA[®] can still clearly differentiate by its MOA, replacing the missing protein of CI-INH”

Additional HCP Quotes

“From our collective experience, we gave efficacy 5. I have some Cinryze patients that still have breakthrough attacks but haven’t had any with HAEGARDA[®] .”

— HAE HCP

— Leading KOL

==> picture [43 x 43] intentionally omitted <==

==> picture [42 x 42] intentionally omitted <==

==> picture [42 x 43] intentionally omitted <==

Additional Patient Testimonials

“I never realized how much HAE limited me until it stopped being a big part of my life.”

— Shari, HAEGARDA[®] patient

“When I started HAEGARDA[®] , I went longer without an attack than I had in over 18 years.”

— Stephanie, HAEGARDA[®] patient

“For 40 years I lived with so many limitations, until HAEGARDA[®] . I’m still getting used to a new way of life.” — Melissa, HAEGARDA[®] patient

“She started HAEGARDA[®] …and literally her life changed. She said she owed it all to HAEGARDA[®] . I cried with this woman. And she didn’t have any attacks. She started HAEGARDA[®] and was attack free.”

— HAE HCP, MD

“Maybe the most important part of the guidelines is the emphasize of C1 inhibitors as first line. No matter how you feel about guidelines, its still number one.”

— HAE HCP, MD

“C1-INH has been around for 35 years. It is a trusted product.” — HAE HCP, MD

96 | Driven by Our Promise[™]

Cardiovascular Disease (CVD) High Unmet Medical Need

==> picture [385 x 244] intentionally omitted <==

CVD remains leading cause of death globally
In the US & Europe, 2 million MI’s occur each year
Survivors remain at high risk for early recurrent CV events
Among high-risk populations:
14% recurrence in year one
of these ~70% within first 90 days
Reducing the risk of early recurrent events represents a significant unmet need

97 | Driven by Our Promise[™]

CSL112 – Our Vision and Strategy

==> picture [402 x 265] intentionally omitted <==

Vision

Establish CSL112 as a leading hospital initiated solution to prevent early recurrent CV events in post-AMI pathway of care

Strategy

Define the unmet need within the 90d period • Establish the role of Apo A-I and Cholesterol Efflux • Position CSL112 in the post AMI pathway of care • Define the clinical and economic value of CSL112

98 | Driven by Our Promise[™]

CSL112 – Our Journey

Expanding patient focus to heart disease, the leading cause of death W/W

==> picture [198 x 169] intentionally omitted <==

Refining high-risk AMI target population and validating with real world data
Developing insights relative to the post-MI pathway of care
Engaging with hospitals and payors to define value proposition and pricing
Building insight and partnerships through Advisory Boards and Scientific exchange
Developing a global Disease Awareness educational program
Partnering with hospitals, payers and patients to prepare the market

99 | Driven by Our Promise[™]

Transplant Opportunity

Two fundamental types of transplant:
Solid organ transplant (SOT)
Hematopoietic stem cell transplant (HSCT)
Transplant is amongst the most transformative and curative therapies in all of medicine
Utility is currently restricted due to
Treatment-related toxicities
Demand outstrips availability of healthy compatible donors

==> picture [359 x 150] intentionally omitted <==

Reducing complications could significantly increase utilisation

100 | Driven by Our Promise[™]

Transplant Strategy

==> picture [838 x 362] intentionally omitted <==

----- Start of picture text -----

1. Reduce Complications (e.g. AMR) IVIG, C1-INH, anti-IL6
SOT
2. Improve Organ Function AAT, C1-INH
3. Organ Availability and Viability
2018 2023 2028 2033
Unmet Needs
&
Leadership
Opportunities
1. Reduce Complications (e.g. GVHD) AAT
2. Adjunct T-Cell Therapy
HSCT
----- End of picture text -----

| Driven by Our Promise[™]

101

Transplant Fit for CSL

Significant unmet patient needs
Multiple opportunities with current assets with proof-of-concept evidence
Limited competition and concentrated call points
Building on our strong foundation of plasma assets
Potential to expand use of Hematopoietic Stem Cell Transplant

==> picture [318 x 311] intentionally omitted <==

102 | Driven by Our Promise[™]

Summary

==> picture [409 x 429] intentionally omitted <==

103 | Driven by Our Promise[™]

R&D Portfolio - December 2018

	RESEARCH	PRE-CLINICAL	PHASE I	PHASE II	PHASE III	REGISTRATION	COMMERCIAL / PHASE IV
New Product Development	Emerging Technologies	CSL787 Nebulised Ig	CSL730 rFc Multimer	CSL312 Anti-FXIIa in HAE	Clazakizumab Transplant*		IDELVION®
	Novel Strategies	CSL311 Anti-BC	CSL324 Anti-G-CSF	Mavri GM-CSFR-AZ*	pdFVIII Ruide		AFSTYLA®
	Discovery Projects	CSL200 (CAL-H) SCD	CSL346 Anti-VEGF-B		CSL112 Apo-AI		FLUAD® aTIV 65+ yr US, UK, AUS
	Haptoglobin	CSL889 Hemopexin in SCD	CSL334 IL-13R ASLAN*		FLUAD QIV 65+ yr		FLUCELAX® QIV 4+ yr US
	Clinical Applications	P. gingivalis/POD OH-CRC*			Pre-Pandemic Vaccine (aH5N1c)		CSL830 C1-INH Subcut EU
Life Cycle Management / Market Development	Clinical Applications	C1-INH New Indications			PRIVIGEN® ID Japan		PRIVIGEN® CIDP US
		Fibrinogen New Formulations			HIZENTRA® IIM	AFLURIA® QIV 6m-4 yr AUS	HIZENTRA® CIDP
					CSL842 C1-INH AMR	PRIVIGEN® CIDP Japan	KCENTRA® Japan
					CSL964 AAT GvHD Prevention	HIZENTRA® CIDP Japan	HAEGARDA® US
							AFLURIA® QIV 6m+ US

*Partnered Projects

104 | Driven by Our Promise[™]

Current CSL Behring Therapeutics Platform

==> picture [404 x 361] intentionally omitted <==

----- Start of picture text -----

Breakthrough
Medicines Transplant
Immunoglobulins
Specialty
Products
Haemophilia
Products
Plasma Recombinant
Fractionation Technology
Gene Therapy
Protein Science
----- End of picture text -----

105 | Driven by Our Promise[™]

Future CSL Behring Therapeutic Area Framework

==> picture [388 x 285] intentionally omitted <==

----- Start of picture text -----

Immunology and Neurology
Haematology and Thrombosis
Transplant
Respiratory
Cardiovascular and Metabolic
Plasma Recombinant Gene and Cell
Fractionation Technology Therapy
----- End of picture text -----

106 | Driven by Our Promise[™]

R&D Portfolio - December 2018

	RESEARCH	PRE-CLINICAL	PHASE I	PHASE II	PHASE III	REGISTRATION	COMMERCIAL / PHASE IV
New Product Development	Discovery Projects	CSL787 Nebulised Ig	CSL730 rFc Multimer	CSL312 Anti-FXIIa in HAE	Clazakizumab Transplant*		IDELVION®
	Discovery Projects	CSL311 Anti-BC	CSL324 Anti-G-CSFR	Mavri GM-CSFR*	pdFVIII Ruide		AFSTYLA®
	Discovery Projects	CSL200 (CAL-H) SCD	CSL346 Anti-VEGF-B		CSL112 Apo-AI		FLUAD® aTIV 65+ yr
	Discovery Projects	CSL889 Hemopexin in SCD	CSL334 IL-13R ASLAN*		FLUAD QIV 65+ yr		FLUCELVAX® QIV 4+ yr US
	Discovery Projects	P. gingivalis/POD OH-CRC*			Pre-Pandemic Vaccine (aH5N1c)		CSL830 C1-INH Subcut EU
Life Cycle Management / Market Development	Clinical Applications				PRIVIGEN® PID Japan	FLUCELVAX® QIV 9+ yr EU	PRIVIGEN® CIDP US
	Clinical Applications				HIZENTRA® IIM	AFLURIA® QIV 6m-4 yr AUS	HIZENTRA® CIDP
	Clinical Applications				CSL842 C1-INH AMR	PRIVIGEN® CIDP Japan	KCENTRA® Japan
	Clinical Applications				CSL964 AAT GvHD Prevention	HIZENTRA® CIDP Japan	HAEGARDA® US
	Clinical Applications						AFLURIA® QIV 6m+ US

*Partnered Projects

| Driven by Our Promise[™]

107

Expected Progress in Next 12 Months

==> picture [913 x 73] intentionally omitted <==

----- Start of picture text -----

New Product Product Dev. & Registration Post
Research Phase I (FIH) Phase II Phase III
Opportunity GLP Toxicology & Launch Registration
1 2 3 4 5 6 7
----- End of picture text -----

	1	2	3	4	5	6	7
En Rese	ter arch Enter P Dev. & G	roduct LP Tox. Enter	Phase I Enter P	hase II Enter P	hase III Enter R & La	egister unch Enter Regist	Post ration

	Clin Applications & Discovery		CSL889 Hemopexin in SCD	PRIVIGEN SSc	HIZENTRA IIM	PRIVIGEN ID Japan	HIZENTRA® CIDP Japan
	Clin Applications & Discovery	CSL200 (CAL-H) SCD	CSL312 (Anti-FXIIa) in Thrombosis	HIZENTRA SSc		IDELVION® 21 Day Dosing	PRIVIGEN® CIDP Japan
	Clin Applications & Discovery		CSL311 Anti-Beta Common	CSL324 Anti-G-CSFR Ph1b		AFLURIA QIV 6m-4 yr AUS	CSL830 C1-INH Subcut EU
	Clin Applications & Discovery		CSL787 Nebulised Ig	CSL346 Anti-VEGF-B Ph1b	CSL964AAT GvHD Prevention	FLUCELVAX QIV 9+ yr EU
	Clin Applications & Discovery		CSL200 (CAL-H) SCD	CSL819 C1-INH Kidney DGF		FLUAD QIV 65+ yr
						Pre-Pandemic aH5N1c US

108 | Driven by Our Promise[™]

Significant Target Launch Dates

2018	2019	2020	2021-2024
HIZENTRA® CIDP US/EU	HIZENTRA® CIDP Japan	PRIVIGEN® PID Japan	CSL312 (Anti-FXIIa) HAE
PRIVIGEN® CIDP US	PRIVIGEN® CIDP Japan	IDELVION® 21 Day Dosing	Hizentra® IIM
CSL830 C1-INH Subcut EU			Improved Fibrinogen
Kcentra Japan			CSL112 ApoA-I
			*Clazakizumab Transplant**
			IVIg Kidney AMR
AFLURIA® QIV 6m+ US			CSL842 C1-INH AMR
AFLURIA® QIV 5-17yr AUS	AFLURIA® QIV 6m to 5yr AUS		FLUCELVAX® QIV 4+ yr AUS
FLUAD® aTIV 65+ yr UK, AUS	FLUCELVAX® QIV 9+ yr EU	FLUAD® aQIV 65+ yr US	FLUAD® aQIV 65+ yr EU

109 | Driven by Our Promise[™]

2018 Highlights

Immunology & Neurology Haematology & Thrombosis Transplant Cardiovascular & Metabolic Respiratory Licensing & Vaccine	• Completion of CSL324 (anti-G-CSF) Phase I study • Initiation of CSL312 (anti-FXIIa) HAE Phase II study • Initiation of CSL730 (rec FC multimer) Phase I study • PRIVIGEN® CIDP and HIZENTRA® CIDP approved in the US
	• Ongoing IDELVION® dosage extension study supports 21 day regimen • Initiation of CSL200 (CAL-H) in SCD GTP Toxicology studies
	• CSL842 C1-INH AMR Phase III actively recruiting and on track • Successful FDA Type C meeting regarding Clazakizumab (anti-IL6) study
	• Initiation of CSL112 (Apo A-1) Phase III study (AEGIS-II) • Completion of CSL346 (Anti-VEGF-B) Phase 1 study
	• Initiation of CSL787 Nebulised Ig GLP Toxicology studies
	• AFLURIA® QIV registered in US for 6M-4years • FLUAD® aTIV registered in UK and Australia • FLUCELVAX® QIV positive effectiveness data compared with egg-based vaccines in US 2017-18 season • Initiation of CSL334 IL-13R Phase I study by ASLAN s*

110 | Driven by Our Promise[™]

Q&A

==> picture [409 x 429] intentionally omitted <==

111 | Driven by Our Promise[™]

For immediate release 5 December 2018

==> picture [55 x 28] intentionally omitted <==

==> picture [115 x 25] intentionally omitted <==

Next Generation Cell-based Influenza Vaccine Shows Significantly Greater Effectiveness Compared to Standard Egg-based Options in the 2017-18 US Influenza Season

CSL spotlights developments in cell-based vaccine technology at Australian Research and Development briefing

CSL Limited (ASX:CSL; USOTC:CSLLY) subsidiary Seqirus, today presented new real‐world data showing that its cell‐based quadrivalent influenza vaccine (QIVc) was 36.2 percent more effective than standard* egg‐based quadrivalent vaccines (QIVe) in preventing influenza‐like illnesses during the 2017/18 influenza season in the United States. This is likely due to the predominance of the H3N2 virus and its propensity for mutation when it is adapted for influenza vaccine production in chicken eggs. These observational data were presented today at the Canadian Immunisation Conference and also shared at CSL’s annual Research and Development briefing in Sydney.

The finding is based on an analysis of over one million (1,353,862) medical records for patients aged four years and above who received either a four‐strain egg‐based influenza vaccine or a four‐strain cell‐based influenza vaccine in a primary care setting during the 2017/18 influenza season in the United States. Analysing real‐world data from electronic medical records is a new and important approach to understanding the effectiveness of influenza vaccines and their impact on health outcomes. These types of analyses are different from traditional randomised clinical trials which study clinical efficacy.

According to the US Centers for Disease Control[1] the 2017/18 influenza season in the US was the worst in recent years with the H3N2 virus being associated with the majority of influenza infections. Research has shown that H3N2 viruses often undergo changes when they are grown in eggs[2] . When produced completely outside of the egg‐based process, cell‐based influenza vaccines avoid egg‐adapted changes, which means they may offer a closer match and potentially improved protection compared to standard egg‐based options in some seasons.[3, 4, ] 5, 6, 72,3,4,5,6,7

QIVc was first licensed in the US in 2016 based on a study showing non‐inferiority immune response to a three‐strain cell‐based influenza vaccine. Both cell‐based products used in this study were produced using egg‐based starting viruses.[8] The 2017/18 season was the first in which QIVc was manufactured using a cell‐derived H3N2 starting virus, making this component of the vaccine exclusively cell‐based. Seqirus is incorporating other cell‐derived starting viruses into the production process for QIVc and has plans to conduct real‐world studies over future seasons to help determine the full potential of the cell‐based technology in preventing influenza.

*standard QIVe is non‐adjuvanted with standard dose of antigen.

For more information about CSL Limited, visit www.csl.com.au Page 1 of 4

==> picture [93 x 6] intentionally omitted <==

For immediate release 5 December 2018

==> picture [55 x 28] intentionally omitted <==

==> picture [115 x 25] intentionally omitted <==

“The real‐world data, along with other emerging evidence, indicates that cell‐based influenza vaccines may result in better influenza‐related outcomes compared to standard egg‐based vaccine options in some seasons, particularly those seasons characterised by egg‐adapted changes,” said Gregg Sylvester, VP Medical Affairs, Seqirus. “We are greatly encouraged by the data and with increasing availability of our vaccine look forward to working with partners to generate additional data in future seasons.”

Developing new and better influenza vaccine technologies is a strategic priority for Seqirus, including further advancing current cell‐based technology as well as adjuvants – or ‘immune boosters’ – to enhance the immune response of those particularly vulnerable to influenza such as children and the elderly.

While QIVc is currently only licensed in the US, the European regulatory agency (EMA) recently issued a positive recommendation for the vaccine, indicating formal approval in Europe by the end of 2018. Expansion into other markets is planned after that, including the submission of an application to the TGA in Australia in 2019.

Seqirus’ QIVc is manufactured in the company’s Holly Springs facility in North Carolina. The capacity of the plant to meet anticipated future demand for the vaccine has been greatly enhanced with approval by the FDA earlier in 2018 for important process improvements to the manufacturing process, and by the recently announced US$140 million plant expansion.

"The burden of influenza is a global healthcare concern, and Seqirus is committed to developing new and potentially better vaccines that help reduce the hundreds of thousands of deaths and severe illness caused every year by influenza. Since we acquired the cell‐based technology just three years ago, we have increased vaccine production five‐fold and introduced cell‐derived starting viruses (rather than viruses that have been optimised to grow in eggs). These innovations together with other major investments into the Holly Springs facility will assist us to meet further global demand for the vaccine," said CSL’s Chief Scientific Officer Professor Andrew Cuthbertson.

Influenza is a common, highly contagious infectious disease that can cause severe illness and life‐threatening complications in many people. In Australia, the impacts of the 2017 season included high levels of absenteeism and a substantial burden on primary care and hospitals.[9]

“Vaccination is the best line of defence in reducing deaths and severe illness caused by influenza. Every flu season is different and it’s important that we stay one step ahead of influenza viruses through the development of more effective vaccines, better matched to the strains in circulation. This real‐world data on cell‐based vaccines is encouraging and will bring another welcome influenza vaccine option to Australia,” said Professor Terry Nolan AO, Head, Melbourne School of Population and Global Health. ‐ ends ‐

Media Contact

Christina Hickie CSL Limited Phone: +61 9389 3425/ 0429 609 762

For more information about CSL Limited, visit www.csl.com.au

Page 2 of 4

==> picture [93 x 6] intentionally omitted <==

For immediate release 5 December 2018

==> picture [55 x 28] intentionally omitted <==

==> picture [115 x 25] intentionally omitted <==

About the Study: Data from a large U.S. electronic medical record (EMR) provider for primary care practices were obtained between August 1, 2017 and March 31, 2018. This was a retrospective cohort study with the objective of determining the relative vaccine effectiveness ( rVE ) of cell‐based quadrivalent, inactive influenza vaccine (QIVc) compared to that of egg‐ based, quadrivalent, inactive influenza vaccine (QIVe). The endpoint assessed was influenza‐ like illness (ILI), as defined by CDC, which is a widely used set of symptoms that serves as an indicator for people who have influenza infection and reflects exposure and outcome experiences during routine clinical practice.

The analysis included data from people 4 years and older in primary care setting, 92,192 who received QIVc and 1,255,983 who received a QIVe. Exposures were derived from recorded immunizations in individual patients EMRs.

The rVE estimated from the study’s primary analysis indicated that QIVc was more effective than standard egg‐based QIVs in preventing ILI (rVE of 36.2%, 95% CI (26.1,44.9; P<0.001)). Potential study limitations were minimised using stringent quality control of the data set, cross‐referencing the exposure classification step, evaluating two different outcomes code sets for ILI, adjusting for key variables and conducting multiple sensitivity analyses.[10] There are currently no head to head clinical trials comparing the efficacy QIVc to QIVe.

Quadrivalent cell‐culture influenza vaccine is not approved in Australia.

About Seasonal Influenza: Influenza is a common, highly contagious infectious disease that can cause severe illness and life‐threatening complications in many people. To reduce the risk of more serious outcomes, such as hospitalization and death, resulting from influenza, the CDC encourages annual vaccination for all individuals aged 6 months and older.[11] Because transmission to others may occur one day before symptoms develop and up to 5 to 7 days after becoming sick, the disease can be easily transmitted to others.[12] Influenza can lead to clinical symptoms varying from mild to moderate respiratory illness to severe complications, hospitalization and in some cases death. The CDC estimates that 959,000 people in the United States were hospitalized due to influenza‐related complications during the 2017/18 influenza season. Since it takes about 2 weeks after vaccination for antibodies to develop in the body that protect against influenza virus infection, it is best that people get vaccinated to help protect them before influenza begins spreading in their community.[9]

About CSL: CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life‐saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus ‐ provides life‐saving products to more than 60 countries and employs 22,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL Limited, visit www.csl.com.

==> picture [93 x 6] intentionally omitted <==

For more information about CSL Limited, visit www.csl.com.au Page 3 of 4

For immediate release 5 December 2018

==> picture [55 x 28] intentionally omitted <==

==> picture [115 x 25] intentionally omitted <==

REFERENCES:

1 Centers for Disease Control and Prevention (CDC). (2018). Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States — 2017–2018 influenza season. Retrieved from: https://www.cdc.gov/flu/about/burden/estimates.htm Accessed November 2018. 2 CDC. (2018). Advisory Committee on Immunization Practices (ACIP) Presentation Slides: June 2018 Meeting. Retrieved from https://www.cdc.gov/vaccines/acip/meetings/slides‐2018‐06.html Accessed November 2018.

3 Rajaram S., Van Boxmeer J., Leav B., et al . (2018). Retrospective evaluation of mismatch from egg‐ based isolation of influenza strains compared to cell‐based isolation and the possible implications for vaccine effectiveness. Presented at IDWeek 2018, October 2018.

4 Zost S.J., Parkhouse K., Gumina M.E., et al. (2017). Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg‐adapted vaccine strains. PNAS , 114(47)12578‐12583. doi:10.1073/pnas.1712377114.

5 Wu N.C., Zost S.J., Thompson A.J., et al. (2017). A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLOS Pathogens , 13(10): e1006682. doi:10.1371/journal.ppat.1006682.

6 The Francis Crick Institute. (2018). Worldwide Influenza Centre: Annual and Interim Reports – February 2018 interim report. Retrieved from https://www.crick.ac.uk/research/worldwide‐influenza‐ centre/annual‐and‐interim‐reports/ Accessed November 2018.

7 ‐ CDC. (2018). Cell‐Based Flu Vaccines. Retrieved from: https://www.cdc.gov/flu/protect/vaccine/cell based.htm Accessed November 2018.

8 Flucelvax Quadrivalent – Seqirus Inc. 07/2018 (revision 2) Highlights of Prescribing Information: https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM619588.pdf 9 Australian Government Department of Health. 2017 Influenza Season in Australia – A summary from the National Influenza Surveillance Committee, Information Brief 22 Nov, 2017: http://www.health.gov.au/internet/main/publishing.nsf/Content/097F15A91C05FBE7CA2581E20017F0 9E/$File/2017‐season‐summary‐22112017.pdf

10 Armed Forces Health Surveillance Center (AFHSC): Influenza‐Like Illness (ILI). (2015). Retrieved from https://www.health.mil/Reference‐Center/Publications/2015/10/01/Influenza‐Like‐Illness Accessed November 2018.

11 CDC. (2018). Key facts about seasonal flu vaccine. Retrieved from: http://www.cdc.gov/flu/protect/keyfacts.htm Accessed November 2018.

12 CDC. (2018). How flu spreads. Retrieved from: https://www.cdc.gov/flu/about/disease/spread.htm Accessed November 2018

==> picture [93 x 6] intentionally omitted <==

For more information about CSL Limited, visit www.csl.com.au Page 4 of 4

AI assistant

CSL Ltd. — Investor Presentation 2018

17854_rns_2018-12-04_69b71344-0924-419d-a06b-95fc56c5dd97.pdf

5 December 2018

Annual Research & Development Investor Briefing

Legal Notice

Forward looking statements

Trademarks

Agenda

Introduction and Highlights

Commitment to Research and Development

Key Past Launches from R&D Portfolio

Leveraging Global Capabilities

R&D Portfolio - December 2017

Progress Through Stage Gates in 2018

R&D Portfolio - December 2018

Core Capabilities: Immunoglobulins | Haemophilia | Specialty Products | Breakthrough Medicines | Transplant | Vaccines & IP

Seqirus Influenza Vaccines

Influenza Viruses Mutate in Various Ways

Seqirus Technologies aim to Enhance Influenza Vaccines

Milestones in 2018

Successful completion of AFLURIA QIV program

Improvements in FLUCELVAX manufacturing output

Number of doses of FLUCELVAX manufactured by calendar year

Vaccine Seed Adapts to Grow in Eggs

No Adaptation Required in Generation of Cell Seed

Science describes specific adaptation required for virus to grow in eggs, especially (but not only) H3N2

H3N2-dominant seasons occur often and can be associated with a substantial health burden

US 2017-18 Season was Severe and Dominated by H3N2

Big Data to Assess Real World Health Impact of a Vaccine

Relative VE of cell- vs egg-based vaccines in 2017-18 US Season

Klein et al, Vaccine Effectiveness of Flucelvax Relative to IIV During the 2017-18 Influenza Season in Northern CA. IDWeek October 2018, San Francisco, CA (Late Breaker 15).

Francis Crick Institute (WHO) 15 year data Cell- vs egg-based “reference virus” similarity to wild-type H3N2

Virus collection date

MF59 Adjuvant

FLUAD is Gaining Wider Usage for People 65yrs and Older

Real World Data to Investigate the Potential Benefits of FLUAD

Seqirus Technologies aim to Enhance Influenza Vaccines

Anticipated Milestones in 2019

• FLUAD QIV

CSL Behring Research and Early Development Portfolios Dr Andrew Nash Senior Vice President, Research

Research Organisation and Portfolio

Research Organisation and Portfolio

Early Development Portfolio

• Portfolio of preclinical and early-mid stage clinical opportunities consistent with CSL commercial objectives

• Delivery of high quality candidates for clinical development

Immunoglobulin Therapy

Immunoglobulin Therapy

Targeting FcRn – IG vs. anti-FcRn agents

Anti-FcRn therapy

Immunoglobulin Therapy

Mechanism of action summary

CSL730 – Recombinant Fc Multimer

Immunoglobulin Therapy – Expanding Benefit

Nebulised Ig – respiratory tract infections

Immunoglobulin Therapy – Expanding Benefit

Inhaled IgG prevents bacterial and viral infection

CSL312 – HAE and Thrombosis

CSL312 – HAE and Thrombosis

First in Human (healthy volunteers) Phase I study

CSL324 – Neutrophil Mediated Inflammation

G-CSF / Neutrophils / Inflammation

CSL324 – Neutrophil Mediated Inflammation

First in Human (healthy volunteers) Phase I study

CSL324 – Neutrophil Mediated Inflammation

Hidradenitis Suppurativa (Acne Inversa)

Palmoplantar pustulosis

CSL324 – Neutrophil Mediated Inflammation

Kidney graft reperfusion injury

CSL324 – Neutrophil Mediated Inflammation

Kidney graft reperfusion injury

Research and Early Development

Commercial Market Overview

Targeted Protein Therapeutic Market

CSL Portfolio

New Product Launches

Immunoglobulin Market

Global IG volume by indication 9% Growth

Growth Drivers

CSL Portfolio: Immunoglobulin

CSL Ltd. Investor Presentation 2018